By some accounts, the rate of participation in clinical trials is as low as 3 percent of potential trial candidates, and that’s with more than 14,000 oncology trials actively recruiting patients. In an effort to enhance patient recruitment, oncology-focused Worldwide Clinical Trials has formed a strategic partnership with Deep Lens to harness VIPER, its AI-driven digital pathology platform.
The alliance is designed to fast-track cancer diagnoses and provide improved treatment and clinical trial options more quickly by bolstering collaboration between care teams, research teams and patients. The companies plan to develop a pilot study using new clinical trial designs and insights via the VIPER platform.
“Cancer research is advancing at an incredible pace,” Deep Lens co-founder and CEO Dave Billiter told Clinical Trials Arena. “We need to up our game as pathologists and CROs to deliver increased precision, speed and communication to find patients with particular disease subtypes or biomarkers.
“With the global reach and scientific and operations expertise of Worldwide, we believe we can streamline clinical trial recruitment. And, just as importantly, oncologists can inform patients and their caregivers about clinical research options from day one.”
- FierceBiotech: Worldwide Clinical inks partnership deal with Deep Lens
- Clinical Trials Arena: Worldwide, Deep Lens partner to streamline oncology trial recruitment